A new partnership to improve TB treatments around the world

 

endTB aims to find shorter, less toxic and more effective treatments for ‘multidrug-resistant TB’ (MDR-TB) through:

  • access to new drugs
  • a clinical trial
  • advocacy at national and global levels.

Covering 17 countries, the project is a partnership between Partners In Health, Médecins Sans Frontières, Interactive Research & Development and financial partner UNITAID.

Watch the two-minute animation

 

You can contact us, or follow us on Twitter.

endTB clinical trial, one year on

Bedaquiline. (Daro Sulakauri / MSF)

 

24 March 2018

On World TB Day Dr. Lorenzo Guglielmetti, endTB trial co-principal investigator, takes stock of progress in the trial's first year.

Read more

The Lancet: new safety and efficacy findings

Patient holding his medication, he takes up to 26 pills a day to treat XDR-TB. Here he holds his morning selection, which includes delamanid, one of the newest DR-TB drugs, which he is taking for the first time today.

 

14 February 2018

An MSF study on the combined use of new TB drugs in Armenia, India and South Africa shows promising results.

Read more

PIH MSF MSF UNITAID